<DOC>
	<DOCNO>NCT01943526</DOCNO>
	<brief_summary>The objective study assess long-term safety impact disease activity progression natalizumab ( Tysabri ) participant relapse remit multiple sclerosis ( RRMS ) clinical practice setting .</brief_summary>
	<brief_title>Ireland Natalizumab ( TYSABRI ) Observational Program</brief_title>
	<detailed_description>iTOP retrospective prospective Irish observational study participant receive natalizumab , participant follow 3 year . This study design address long-term safety profile long-term impact disease activity progression natalizumab market use . Collection efficacy safety data 6- monthly interval coincide regular clinic visit routine clinical practice therefore undertaken iTOP observational period .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Must give write informed consent assent , applicable . Decision treat natalizumab must precede enrollment . Patient characteristic contraindication treatment natalizumab accordance prescribe information . Must receive natalizumab ( Tysabri ) treatment RRMS accordance natalizumab indication statement . Must document diagnosis Relapsing Remitting Multiple Sclerosis ( RRMS ) . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ireland</keyword>
	<keyword>Natalizumab</keyword>
</DOC>